Cranberry (Vaccinium macrocarpon)
1. Identity: Botanical Classification, Natural Source, and Common Forms
Botanical and Chemical Identity
Cranberry (Vaccinium macrocarpon Ait.) is an herbaceous, evergreen, dwarf shrub of the genus Vaccinium in the family Ericaceae, often used as a functional food. There are two major species of cranberry: the American cranberry (Vaccinium macrocarpon) and the European cranberry (V. oxycoccos). The European cranberry fruit is smaller (0.6–1.2 cm) and only half the size of the American fruit. The American cranberry, which is frequently cultivated, is a member of the Ericaceae family, evergreens, creeping shrubs native to the cool, temperate, acidic soils and peat wetlands of Northeastern United States and southern Canada.
Cranberries are primarily distributed in the northern United States — including Massachusetts, Wisconsin, and Maine — as well as in Quebec, Canada; Chile in South America; and northeastern Europe. They are also found in China's Greater Khingan Range and Fuyuan City, Jiamusi, Heilongjiang Province. The United States and Canada together account for more than 90% of the world's production.
It is an evergreen shrub characterized by rounded or obovate leaves, white or reddish campanulate flowers, and purplish-red berries. The plant produces stolons (horizontal stems) having a height of up to 6 feet (2 m). Short, vertical branches, or uprights, 2–8 inches (5–20 cm) in height, grow from buds on the stolons, and these can be either vegetative or fruiting. Each fruiting upright may contain as much as seven flowers.
Common Forms and Preparations
About 95% of the cranberries cultivated are processed into products such as juice drinks, sauce, and sweetened, dried cranberries. As a dietary supplement, cranberry is available in multiple forms: whole dried fruit, juice cocktails, unsweetened juice, standardized capsules and tablets, and concentrated powder extracts. Cranberry supplements are marketed as beneficial for urinary tract health, especially those standardized to contain 36 mg of proanthocyanidins per serving.
2. Traditional and Historical Use
Indigenous North American Use
Native to North America, cranberries have been an important food and medicine for Indigenous peoples for thousands of years. The Algonquin, Chippewa, and Cree, among others, gathered wild cranberries where they could find them in what is now Maine, Massachusetts, New Jersey, and Wisconsin, all the way west to Oregon and Washington, and north to areas of British Columbia and Quebec.
The berry was called sassamenesh (by the Algonquin) and ibimi (by the Wampanoag and Lenni-Lenape), which translates literally as "bitter" or "sour berries." Cranberries were used for everything from cooking to dyes for textiles to medicines.
Cranberries were first used by Native Americans, who discovered the wild berry's versatility. Native Americans used cranberries in a variety of foods, the most popular being pemmican, a high-protein combination of crushed cranberries, dried deer meat, and melted fat. They also used it as a medicine to treat arrow wounds and as a dye for rugs and blankets.
According to historical accounts, Native Americans ate cranberries as fresh fruit, dried the fruit and formed them into cakes to store, and made tea out of the leaves. Cranberries have long been used by Indigenous peoples as a remedy for urinary tract health, digestive issues, and infections, especially bladder infections. Iroquois and Chippewa used cranberries for an assortment of medicinal purposes: as "blood purifiers," as a laxative, and for treating fever, stomach cramps, and a slew of childbirth-related injuries. Other medicinal uses of cranberries by the indigenous populations included poultice for wounds, and treatment for indigestion, swelling, blood poisoning, and seasickness.
European Settler and Colonial Use
When European settlers arrived in North America, they quickly recognized the cranberry's value and integrated it into their own traditional medicine practices. They identified the cranberry's high vitamin C content, using it to ward off scurvy, a common disease amongst sailors and explorers caused by vitamin C deficiency. Consuming cranberries became a common preventative measure, and the fruit was often taken on long sea voyages for this purpose.
Cranberries have loads of vitamin C and benzoic acid, a natural preservative, so they made a perfect ship's provision stored in barrels. European settlers used cranberries in a way similar to how they would have used other sour fruits — as a sour fruit sauce with wild fowl.
3. Key Constituents and Active Compounds
Proanthocyanidins (PACs)
The key feature of cranberry's effectiveness is its anti-adhesion properties, mainly due to the presence of unique A-type proanthocyanidins (PACs). These compounds disrupt the ability of P-fimbriated Escherichia coli, the most common bacteria causing urinary tract infections, to adhere to the epithelial cells lining the urinary tract. A-type PACs are believed to bind specifically to the P-fimbriae on the surface of E. coli, altering the bacterial cell surface and preventing attachment to uroepithelial cells.
Cranberry proanthocyanidins contain A-type linkages and have been associated with preventing adhesion of P-fimbriated uropathogenic Escherichia coli to uroepithelial cells. This A-type linkage structure is distinct from the B-type proanthocyanidins found in other common foods such as grapes, apples, green tea, and dark chocolate. Cranberry juice cocktail containing A-type proanthocyanidins exhibited bacterial anti-adhesion activity in human urine when compared to foods containing B-type proanthocyanidins.
Anthocyanins and Flavonols
Cranberry (Vaccinium macrocarpon) is known for its phytochemical content, including flavonol glycosides, anthocyanins, and proanthocyanidins, which exhibit anti-inflammatory effects. The anthocyanins responsible for cranberry's deep red color include cyanidin, peonidin, and malvidin derivatives. Other phenolic components in cranberries, such as myricetin and quercetin, were also suggested to inhibit the adhesion of P-fimbriated E. coli to human bladder cells in vitro.
Other Bioactive Compounds
Bioactive constituents in the plant include flavonol and anthocyanin glycosides, oligomeric proanthocyanidins, substituted hydroxycinnamic acids and derivatives, other organic acids, iridoids, carotenoids, and triterpenoids.
Cranberry fruit contains the triterpenoid ursolic acid (UA) in its peel, existing in aglycone form as well as in cis and trans p-hydroxycinnamate esters. Quantitative analysis by LC-MS has determined the UA content of the whole cranberry fruit of different cultivars to be between 60 and 110 mg per 100 g of fresh fruit.
Cranberries also contain the carotenoid lutein, as well as other carotenoids in lesser quantities. Many ingested proanthocyanidins are degraded by the gut microbiota into various phenolic acids, including benzoic, phenylacetic, and phenylpropionic acids. Several of them were suggested to inhibit P-fimbriated E. coli adherence to human bladder cells in vitro. Hippuric acid is a major metabolite of polyphenols in human urine after cranberry consumption.
Dual Anti-Adhesion Components
The anti-adhesion effect against uropathogens is attributed to two components of cranberries: fructose, which blocks Type 1 fimbriae (sensitive to mannose), and the proanthocyanidins (PACs), which inhibit the P fimbriae (mannose resistant). Multiple phenolic components found in cranberries, including flavonols, proanthocyanidins, anthocyanins, and phenolic acids, have been found to inhibit uropathogenic E. coli adherence.
4. Scientific Evidence by Area of Use
4.1 Urinary Tract Infection (UTI) Prevention
Mechanism: Cranberries contain proanthocyanidins (PACs), which inhibit the adherence of P-fimbriated Escherichia coli to the urothelial cells lining the bladder. In in vitro studies, a significant reduction of UPEC adhesion (up to 75%) on cell lines was observed versus control. For strains of P. mirabilis there was also a reduction of adhesion (up to 75%) compared to controls, as well as a reduction in motility and urease activity.
Clinical Evidence — Cochrane Systematic Review (2023): The 2023 Cochrane update added a further 26 studies, taking the total number to 50 with 8,857 participants. These data support the use of cranberry products to reduce the risk of symptomatic, culture-verified UTIs in women with recurrent UTIs, in children, and in people susceptible to UTIs following interventions. All randomized controlled trials (RCTs) or quasi-RCTs were included. The total number of studies included was 50, resulting in 8,857 randomized participants. Cranberry products (juice/tablet/capsule) were compared with placebo or no specific treatment in 45 studies. 26 of these studies were meta-analyses that assessed for the incidence of symptomatic, culture-verified UTIs while on treatment.
In general, cranberry products may decrease the overall risk of symptomatic, recurrent UTIs in women by 25 percent, and in some cases, by more than 30 percent, according to this Cochrane review. However, the effectiveness of cranberry is still in question because of inconsistent findings.
Compared to antibiotics, cranberry products may make little or no difference to the risk of symptomatic, culture-verified UTIs (2 studies, 385 participants: RR 1.03, 95% CI 0.80 to 1.33; I² = 0%). Compared to probiotics, cranberry products may reduce the risk of symptomatic, culture-verified UTIs (3 studies, 215 participants: RR 0.39, 95% CI 0.27 to 0.56; I² = 0%).
While cranberry may assist in preventing symptomatic UTIs in some women, it is not recommended as a treatment for existing UTIs in any population.
PAC Dose–Response Evidence: A meta-analysis found that when the daily intake of PACs was at least 36 mg, the risk of UTIs was reduced by 18% (RR = 0.82, 95% CI = 0.69–0.98, p = 0.03). When the daily intake of PACs was less than 36 mg, there was no statistically significant risk decrease (p = 0.39). Sub-group analysis showed that cranberries only significantly reduced the risk of UTIs when the duration of cranberry product use fell between 12 and 24 weeks (RR = 0.75, 95% CI = 0.61–0.91, p = 0.004). Additionally, cranberries also significantly reduced the risk of UTIs only in subgroups that included females (RR = 0.84, 95% CI = 0.71–0.98, p = 0.02).
Processing cranberries into various products, like tablets or capsules, can reduce the concentration of PACs, which can reduce the potential effectiveness of a product. Studies in certain populations at increased risk for UTIs, such as elderly people in long-term care and pregnant women, have had inconsistent results.
Specific Clinical Trial: A 24-week, placebo-controlled trial found no overall benefit of cranberry juice compared with placebo for prevention of UTI recurrence in women with a history of frequent UTIs, but women older than 50 (n = 118) had a significantly lower incidence with cranberry. In contrast, a small controlled pilot study in 36 adolescents with recurrent UTIs in which a standardized extract (120 mg cranberry with 36 mg PACs/day for 60 days) added to standard treatment produced significantly fewer UTIs compared to baseline (P = 0.0001) and standard treatment alone (P = 0.0001).
Evidence strength: Moderate to strong for prevention of recurrent UTIs in women and children; weak and inconsistent for elderly populations in long-term care; not supported for treatment of active infections.
4.2 Cardiovascular Health
Cranberries have a unique phytochemical profile and are a particularly good source of proanthocyanins, anthocyanins, flavonoids, and phenolic acids. In vitro studies have shown that cranberry polyphenols exert strong anti-inflammatory and antioxidant properties. However, this does not always translate directly to significant clinical effects, and additional research is needed to identify which CVD risk factors may be modifiable with cranberry juice supplementation.
Results from a meta-analysis indicated that cranberry administration significantly reduced systolic blood pressure and body mass index. No statistically significant change was observed in triacylglycerol, total cholesterol, low-density lipoprotein, or high-density lipoprotein in the pooled data. No statistically significant change was observed in fasting plasma glucose, fasting insulin, homeostasis model assessment of insulin resistance, diastolic blood pressure, waist circumference, C-reactive protein, or intercellular adhesion molecule.
An acute dose of a low-calorie, high-polyphenol cranberry beverage improved antioxidant status, while 8-week daily consumption reduced cardiovascular disease risk factors by improving glucoregulation, downregulating inflammatory biomarkers, and increasing HDL cholesterol. This trial enrolled 78 non-smoking men and women aged 30–70 years with a BMI of 27–35 kg/m² at two study sites.
Cranberry has demonstrated endothelial-dependent vasodilation and reduced arterial stiffness in human studies.
Evidence strength: Preliminary to moderate. Several small RCTs show benefits for specific markers (HDL cholesterol, systolic blood pressure, endothelial function), but the evidence is inconsistent across outcomes and study populations. Larger, longer-duration trials are needed.
4.3 Helicobacter pylori and Gastrointestinal Health
In the last 15 years, cranberry supplementation was investigated to improve the success of eradication of H. pylori infection, which represents the major cause of peptic ulcer disease and gastric cancer. In vitro studies demonstrated the ability of cranberry constituents to exert anti-adhesion activity on H. pylori.
A high-molecular-mass constituent derived from cranberry juice inhibits the sialic acid-specific adhesion of H. pylori to human gastric mucus and to human erythrocytes.
In a prospective RCT, 189 Chinese people with H. pylori infection were randomly divided to receive cranberry juice (250 mL) or placebo for 90 days. At the end of the study, 14 of the 97 subjects (14.43%) in the cranberry juice treatment group had negative results for the 13C-urea breath test (vs. 5 of the 92 in the placebo group) (p < 0.05). Consumption of high-proanthocyanidin cranberry juice twice daily (44 mg proanthocyanidin per 240-mL serving) resulted in a decreased H. pylori infection rate by 20% as compared with low dosages of proanthocyanidins (p < 0.05).
In a multicentric RCT including 295 asymptomatic children (6–16 years of age) who tested positive for H. pylori, they were randomly divided into four groups. Cranberry juice (200 mL) and Lactobacillus johnsonii La1 product (80 mL) were given daily for 3 weeks. At the end of the study, H. pylori eradication rates significantly differed in the four groups: 1.5% in the control group compared with 14.9%, 16.9%, and 22.9% in the La1, CB, and CB/La1 groups, respectively (p < 0.01).
The impact of cranberry supplementation on oral health, gut microbiota, and H. pylori eradication represents one of the most interesting research points, in order to prevent oral health and both gastro-intestinal and extra-intestinal diseases. However, longer RCTs are still lacking and are urgently needed to better understand the role of bioactive molecules of cranberry in oral and gut microbiome modulation.
Evidence strength: Preliminary to moderate for H. pylori suppression; most studies show a modest reduction in infection rate rather than full eradication, and cranberry is not a standalone therapy for this indication.
4.4 Oral Health
With regards to oral health, in vitro studies have shown that cranberry constituents can exert beneficial effects on gingival and periodontal health by inhibiting the host inflammatory response, suppressing bacterial biofilm formation, and reducing the activity of periodontal pathogenic proteolytic enzymes.
A high-molecular-weight cranberry constituent at 0.6 to 2.5 milligrams per milliliter reversed the co-aggregation of 49 (58 percent) of 84 co-aggregating bacterial pairs tested. It acted preferentially on pairs in which one or both members are gram-negative anaerobes frequently involved in periodontal diseases. Thus, the anti-aggregating cranberry constituent has the potential for altering the subgingival microbiota, resulting in conservative control of gingival and periodontal diseases.
Cranberry PACs were demonstrated to prevent the formation of Porphyromonas gingivalis biofilm, and thus to be useful also for oral health. Weiss and colleagues in 2004 incorporated the NDM fraction of cranberry in a mouth rinse, and subjects who used it for 6 weeks reported fewer cariogenic Streptococcus mutans. In another study, a cranberry fraction demonstrated the deactivation of enzymes glucosyltransferase and fructosyltransferase. These enzymes, essential to the formation of glucan and fructan, help the adhesion of streptococci to the tooth surface, thereby inhibiting plaque formation.
However, the high dextrose and fructose content of commercially available cranberry juice makes it unsuitable for oral hygiene use, and the beneficial effect of the high-molecular-weight constituent requires further animal and clinical studies.
Evidence strength: Mostly preclinical (in vitro) with a small number of early-phase human studies. No robust, large-scale RCTs have confirmed clinically meaningful benefits for caries or periodontal disease prevention in humans.
4.5 Gut Microbiota Modulation
A-type proanthocyanidins and their metabolites also interact positively with the intestinal microbiota composition, preventing microbial dysbiosis. Bekiares and colleagues investigated the impact of dried cranberries (42 g/day) consumption on human gut microbiota (n = 10) using the faecal microbiome test; an improvement of Firmicutes/Bacteroidetes ratio as well as of the count of Akkermansia was observed after supplementation. In addition, cranberry powder supplementation (30 g/day) was shown to enhance the production of short-chain fatty acids (SCFAs).
Evidence strength: Preliminary. Studies are small, short-term, and in limited populations. The clinical significance of microbiota changes observed is not yet established.
4.6 Anticancer Properties
Cranberry fruit and foliage contain bioactive compounds that have been found to limit microbial infections, oxidative processes, inflammation, and cell proliferation. Cranberry polyphenols have been shown to deter human cancer cell line proliferation in the oral cavity, colon, and prostate in laboratory settings.
Evidence strength: Preclinical only. Available evidence is restricted to in vitro and animal models. There is currently no established human clinical evidence demonstrating that cranberry prevents or treats cancer.
5. Body Systems and Health Areas Associated with Cranberry
- Urinary tract: Prevention of recurrent UTIs — the most evidence-supported application, particularly through anti-adhesion of uropathogenic E. coli.
- Cardiovascular system: Potential effects on endothelial function, systolic blood pressure, and HDL cholesterol via antioxidant and anti-inflammatory polyphenols.
- Gastrointestinal tract: Anti-adhesion activity against H. pylori; modulation of gut microbiota composition; enhancement of short-chain fatty acid production.
- Oral cavity: Inhibition of cariogenic and periodontopathic bacterial adhesion and biofilm formation.
- Immune/inflammatory system: Anti-inflammatory effects mediated by polyphenols via downregulation of inflammatory biomarkers.
- Oncology (preclinical): Inhibition of cancer cell proliferation in laboratory models of oral, colon, and prostate cancer.
6. Dosage Forms and Dosages Reported in Studies
Cranberry supplements are marketed and studied as beneficial for urinary tract health, especially those standardized to contain 36 mg of proanthocyanidins per serving. That dose of proanthocyanidins appears to decrease the number of urinary tract infections in patients with frequent, recurrent UTIs.
Meta-analysis confirms that when the daily intake of PACs was at least 36 mg, the risk of UTIs was reduced by 18% (RR = 0.82). When the daily intake was less than 36 mg, there was no statistically significant risk reduction.
A small controlled pilot study in 36 adolescents with recurrent UTIs used a standardized extract of 120 mg cranberry with 36 mg PACs per day for 60 days and produced significantly fewer UTIs.
Consumption of high-proanthocyanidin cranberry juice twice daily (44 mg proanthocyanidin per 240-mL serving) resulted in a decreased H. pylori infection rate by 20%.
In the H. pylori RCT, 250 mL of cranberry juice was administered daily for 90 days.
In a cardiovascular RCT enrolling 78 non-smoking men and women, 8 weeks of daily low-calorie, high-polyphenol cranberry beverage consumption reduced cardiovascular disease risk factors by improving glucoregulation, downregulating inflammatory biomarkers, and increasing HDL cholesterol.
In a safety-focused study examining cranberry juice at 240 mL twice daily, this dose did not significantly change the prothrombin time of patients on chronic stable warfarin therapy.
In a gut microbiota study, dried cranberries at 42 g per day were consumed by 10 participants, demonstrating microbiota composition changes. Cranberry powder supplementation at 30 g/day showed enhancement of short-chain fatty acid production.
The ingestion of more than 3 to 4 L per day of cranberry juice may result in diarrhea and other gastrointestinal symptoms; however, clinical trials have recorded few adverse reactions beyond this effect.
7. Safety Considerations and Drug Interactions
General Safety
Although published clinical and animal data indicate that cranberry is not associated with serious adverse effects, interactions with warfarin and kidney stone formation were identified as potential risks. The ingestion of more than 3 to 4 L per day of cranberry juice may result in diarrhea and other gastrointestinal symptoms; however, clinical trials recorded few adverse reactions beyond this effect.
Warfarin Interaction
Cranberry–warfarin interactions in clinical reports have shown bidirectional outcomes. The United Kingdom's Committee on Safety of Medicines has alerted clinicians to a potential interaction between warfarin and cranberry juice and has advised that patients avoid their concurrent use. Review and analysis of the literature revealed that ingestion of large volumes of cranberry juice can destabilize warfarin therapy.
Interactions with warfarin were not associated with moderate intakes of cranberry juice (240–480 mL). Some reports suggested that the potential for warfarin interactions requires excessive intakes of cranberry juice (1–2 L/day) or cranberry extracts (3,000 mg/day).
Cranberry significantly increased the area under the INR–time curve by 30% when administered with warfarin compared with treatment with warfarin alone in one clinical trial involving healthy male volunteers. Separately, 240 mL of cranberry juice twice daily did not significantly change the prothrombin time of patients on chronic stable warfarin therapy. These results contribute to the existing findings of previous randomized, placebo-controlled studies that found no effect of cranberry juice on the anticoagulant properties of warfarin at lower doses.
Cranberry polyphenols have shown inhibitions on the activities of CYP2C9 and CYP3A in laboratory studies, which is the proposed mechanism through which high-dose cranberry could affect warfarin metabolism. Routine INR monitoring is essential and recommended for all patients receiving warfarin therapy who also consume cranberry products regularly.
Kidney Stones (Oxalate)
Studies have reported contradictory data regarding the role of cranberry in kidney stone formation, with some reports suggesting cranberry is associated with a reduced risk of kidney stones. Cranberries do not have high oxalate when eaten as whole or dried fruit; however, cranberry supplements are popular. For most supplements, one capsule per day is recommended, but some brands recommend 1–2 capsules per day. People consuming two capsules of certain supplements could be adding 26–28 mg of extra oxalate to their diet.
A systematic review and meta-analysis reported that insufficient data were available to link cranberry juice to the risk of kidney stones, although some studies have reported that various juices, including cranberry juice, are associated with reducing the risk of kidney stones. One clinical study reported that 500 mL of cranberry juice given to healthy men for 2 weeks had shown favorable effects on risk factors for stone formation (n = 20), which included a decrease in oxalate and phosphate excretion, an increase in citrate excretion, and a decrease in relative supersaturation of calcium oxalate.
Controversy exists over cranberry as a risk factor for the formation of calcium oxalate kidney stones, and the use of cranberry products in individuals with a history of nephrolithiasis probably should be avoided.
Sugar Content
Some commercially available cranberry juice products contain large amounts of sugar. Sugar-free cranberry juice products are also available. This is relevant for individuals with diabetes or glucose intolerance, as the caloric load of sweetened commercial preparations may affect blood glucose management.
Other Potential Interactions
Preliminary evidence suggests that cranberry's anti-adhesion actions might make it useful for treating or preventing cavities or gum disease. However, the sweeteners added to cranberry juice harm teeth, but without sweeteners, cranberry juice is very bitter. This practical consideration limits direct application of commercial cranberry juice products to oral health uses.
References
Go back